L. V. Tse

Evolution of a Functionally Intact but Antigenically Distinct DENV Fusion Loop

This study engineers DENV variants with mutated fusion loops that evade neutralizing antibodies but retain sensitivity to cross-reactive antibodies, offering tools for vaccine development.

Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause severe disease

The paper identifies broadly neutralizing antibodies targeting the S2 region of betacoronavirus spikes that protect against SARS-CoV-1, SARS-CoV-2, and MERS-CoV.

Targeted isolation of panels of diverse human protective broadly neutralizing antibodies against SARS-like viruses

This study isolates a panel of broadly neutralizing antibodies against SARS-like viruses from donors, showing effectiveness against multiple variants including Omicron.

Genetically Engineered DENV Produces Antigenically Distinct Mature Particles

This study genetically engineers DENV to produce antigenically distinct mature particles, offering new tools for vaccine development and maturation studies.

SARS-CoV-2 vaccination induces neutralizing antibodies against pandemic and pre-emergent SARS-related coronaviruses in monkeys

This study shows that SARS-CoV-2 vaccines induce neutralizing antibodies against SARS-CoV-1, SARS-CoV-2, and batCoVs in monkeys.

The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates

This study examines SARS-CoV-2 neutralizing and infection-enhancing antibodies, showing in vitro enhancement does not always lead to in vivo disease enhancement, but can cause increased lung inflammation in monkeys.

Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine and Pyronaridine: In vitro Activity Against SARS-CoV-2 and Potential Mechanisms

This study evaluates the in vitro antiviral activity of three Ebola and Marburg virus inhibitors against SARS-CoV-2 and explores their potential mechanisms of action.

An Engineered Antibody with Broad Protective Efficacy in Murine Models of SARS and COVID-19

This study engineers an antibody, ADG-2, that broadly neutralizes SARS-CoV and SARS-CoV-2 in mice, offering protection against respiratory disease and viral replication.

SARS-CoV-2 D614G Variant Exhibits Enhanced Replication ex vivo and Earlier Transmission in vivo

This study shows the SARS-CoV-2 D614G variant replicates more efficiently and transmits faster in hamsters than the wildtype virus.

Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2

This study designs SARS-CoV-2 nanoparticle vaccines that induce strong neutralizing antibodies in mice, with higher titers and lower doses than existing trimer vaccines.

Broad sarbecovirus neutralizing antibodies define a key site of vulnerability on the SARS-CoV-2 spike protein

The paper identifies broadly neutralizing antibodies against SARS-CoV-2 and related sarbecoviruses, highlighting a conserved epitope on the spike protein as a potential vaccine target.